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Abstract
Background: Although Mycobacterium tuberculosis (TB) infection may cause extrapulmonary disease in HIV-infected
adults, HIV-associated hepatic TB has been poorly characterized. Our objective was to describe hepatic TB in
HIV-infected adults.
Methods: Retrospective study of patients diagnosed with hepatic TB from 2005–2012 at Infectious Diseases Clinic,
King Edward VIII Hospital, Durban, South Africa.
Results: Among twenty cases of histology-confirmed HIV-associated hepatic TB, median CD4 count was 47 cells/μl
(inter-quartile range 27–107 cells/μl) and 75% (15/20) of patients had pre-existing pulmonary TB. The most frequent
clinical finding was hepatomegaly (85%). Liver enzyme abnormalities included elevated alkaline phosphatase
(median 456 u/L, inter-quartile range 322–1,043 u/L) and gamma-glutamyltransferase (median 422 u/L, inter-quartile
range 235–736 u/L). Acid-fast bacilli were cultured from liver tissue in 30% (6/20) of patients; 25% (5/20) identified
as TB. With standard anti-TB therapy, liver enzymes improved within six months in 92% (11/12) of patients. One year
after diagnosis, twelve patients resolved clinically, two patients developed drug-resistant TB and six patients died.
Conclusion: In our case series of HIV-infected patients, hepatic TB occurred in patients with severe immunosuppression,
who presented with hepatomegaly and abnormal liver enzymes. More than half of patients had resolution of liver
function by six months however the 12-month mortality remained high.
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Background
Mycobacterium tuberculosis (TB) and Human Immuno-
deficiency Virus (HIV) cause a high rate of morbidity
and mortality worldwide [1]. Approximately 1.2 million
HIV-infected people developed active TB infection
worldwide in 2014, of which 74% were in sub-Saharan
Africa [2]. In South Africa, more than 50% of TB cases
have HIV co-infection with the risk being greater at
lower CD4 cell counts [2, 3].
Although TB most commonly causes a pulmonary
infection, patients with advanced immunosuppression
are at greater risk of developing extrapulmonary infec-
tion [3]. One manifestation of extrapulmonary TB is
hepatic TB, and the characteristics of HIV-associated
hepatic TB have not been fully described. In the pre-
HIV era a South African study reported a 9.2% preva-
lence of hepatic TB among inpatients with unexplained
hepatomegaly [4].
Hepatic TB can occur as a localized primary infection
or by dissemination of a pulmonary infection, known as
miliary hepatic TB [5]. Local hepatic TB occurs when
ingested TB bacilli cross the gastrointestinal mucosal
barrier to reach the liver via the portal vein [6]. Dissemi-
nated disease via the hepatic artery is more common,
and results in multiple small tubercles in the liver [6].
The clinical, laboratory and radiologic features of
hepatic TB are non-specific [4, 7–12]. Some patients
have liver enzyme abnormalities which may worsen
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during the first few months of anti-retroviral therapy
(ART) [13]. Since liver enzyme abnormalities are varied
and causes may include opportunistic infections, malig-
nancy, HIV cholangiopathy, drug-induced liver injury,
viral hepatitis, hepatic steatosis and immune reconstitu-
tion inflammatory syndrome (IRIS), the diagnosis of hep-
atic TB is challenging and requires a high index of
suspicion [14, 15].
A better understanding of the clinical presentation,
biochemical abnormalities, immunological characteris-
tics, radiographic features, microbiologic findings,
histopathologic findings, and response to treatment of
hepatic tuberculosis will assist in a rational approach to
the interpretation of liver enzyme abnormalities in the
HIV-infected patient. We therefore sought to describe
hepatic TB among HIV-infected patients receiving care
at a tertiary level hospital in Durban, South Africa.
Methods
Data sources
We conducted a retrospective patient chart review at
King Edward VIII Hospital, a tertiary level teaching hos-
pital located in Durban, KwaZulu-Natal. We included all
patients diagnosed with hepatic TB from 2005 to 2012 at
the Infectious Diseases Clinic (IDC), a referral-based
specialist service focused on the management of com-
plex infectious diseases including HIV and TB.
Patients had a thorough clinical examination, laboratory
testing, appropriate imaging, and a liver biopsy at the time
of presentation, and as clinically appropriate. All patients
were treated with standard anti-TB therapy following local
treatment guidelines [16]. We reviewed all available chart
data from initial presentation and follow-up visits.
Patients’ South African identity numbers were used to
search the national Department of Home Affairs records
to determine survival after follow-up.
Diagnosis of Hepatic TB
We included patients as cases in our study if there was
evidence of TB as indicated by a histopathology report
and/or a microbiology report and/or radiologic evidence
of TB at an extra-hepatic site.
All tissue and sputum specimens were stained with
Auramine O stain (Merck KGaA, Darmstadt, Germany)
to detect acid-fast bacilli. Mycobacterial cultures were
performed using the Bactec MGIT system (Becton
Dickinson, New Jersey, USA). The one percent pro-
portion method was used to determine susceptibility of
mycobacterial isolates to isoniazid, rifampicin, strepto-
mycin, kanamycin, and ofloxacin [17, 18].
All tissue specimens were processed and reported on
by a routine clinical histopathology laboratory. Findings
were interpreted in the context of clinical and other
laboratory information. Tissue samples were routinely
assessed for the characteristic histologic pattern consist-
ent with TB. These include:
1 Granulomas - nodular reactions containing
transformed macrophages with or without
surrounding inflammatory cells such as
lymphocytes, eosinophils and multinucleated giant
cells [19, 20].
2 Granulomatous inflammation - a distinctive pattern
of chronic inflammation characterized by aggregates
of activated macrophages with scattered
lymphocytes with or without caseation [20].
Statistical analysis
Study data were collected and managed using Research
Electronic Data Capture (REDCap™), an electronic data
capture tool [21]. All patient variables were analyzed
using Microsoft Excel 2007 (Microsoft Corporation,
Washington, USA).
Results
We identified twenty patients with HIV-associated
hepatic TB (Table 1). Fourteen out of twenty patients
(70%) were female, and median age was 34.5 years
(range 22–58 years). All were HIV-infected and fifteen
out of twenty patients (75%) were ART-naïve. At the time
of liver biopsy, three out of twenty patients (15%) were on
ART for a median of 111 days (range 14–235 days).
The most frequent indication for liver biopsy was an
unexplained liver function test abnormality, with or
without hepatomegaly, in nineteen out of twenty patients
(95%). One patient had a liver biopsy for isolated
hepatomegaly.
At the time of liver biopsy ten patients had smear-
positive pulmonary TB, four smear-negative but culture
positive disease and the remaining three were diagnosed
by suggestive changes on chest radiograph. Eleven patients
(55%) were receiving anti-TB therapy (rifampicin, isonia-
zid, pyrazinamide and ethambutol) for active pulmonary
and/or extra-pulmonary TB disease. Of the three patients
who were on anti-TB therapy for extra-pulmonary TB,
one was diagnosed by a positive mycobacterial blood
culture and the other two on positive culture of pleural
effusion and bone marrow respectively (Table 2).
The median duration of anti-TB therapy at liver biopsy
was 50 days (range 5–219 days). Six out of twenty pa-
tients (30%) had other co-infections: two with Hepatitis
B, two with cryptococcal meningitis, one with herpes
zoster and one with hepatosplenic schistosomiasis.
Clinical and radiographic characteristics of hepatic TB
The most frequent clinical finding was hepatomegaly in
17 (85%) patients (Table 1). Other findings included
generalized lymphadenopathy (60%), pulmonary crackles
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(40%), jaundice (35%), and splenomegaly (30%). One pa-
tient had ascites.
Chest radiograph reports were available for 17 patients
as detailed in Table 1. Abdominal ultrasound reports
were available for only 15 patients. Thirteen reported
hepatomegaly and/or enlarged intra-abdominal lymph
nodes and/or splenic abnormalities, and the remaining
two had normal findings.
Laboratory and histopathology characteristics of
hepatic TB
The median CD4 cell count at the time of liver biopsy was
47 cells/μl (inter-quartile range (IQR) 27–107 cells/μl).
Liver enzymes at the time of biopsy included elevated
alkaline phosphatase (normal range: 42–121 u/l; median
456 u/l, IQR 322–1043 u/l), gamma-glutamyltransferase
(normal range: 10–60 u/l; median 422 u/l, IQR 235–736 u/l)
and alanine transaminase (normal range: 10–45 u/l;
median 46 u/l, IQR 33–95 u/l). All patients had hypo-
albuminaemia (normal range: 32–50 g/l; median 17 g/l,
IQR 16–21 g/l) and eleven out of twenty patients (55%)
had elevated bilirubin levels (normal range: 0–17 μmol/l;
median 21 μmol/l, IQR 14–34 μmol/l). The international
normalized ratio (INR) was normal in nineteen out of
twenty patients (95%) at the time of liver biopsy. The one
patient with an abnormal INR had a value of 1.3 (normal
range: <1.2).
Liver biopsy tissue samples from 14 patients under-
went microscopy and culture (Table 2). All microbiology
samples were negative for acid-fast bacilli (AFB) on
Auramine stain. Five of the 14 (36%) were culture-
positive for TB. All isolates were fully sensitive to isonia-
zid, rifampicin, streptomycin, kanamycin and ofloxacin.
Another patient had mycobacteria isolated from biopsy
tissue but this was not worked up further. Histopatho-
logic findings are detailed in Table 2.
Response to anti-TB therapy and patient outcomes
The changes in serial liver enzyme profiles, as a reflec-
tion of response to anti-TB therapy in the first 6 months,
were available for twelve out of twenty patients (60%).
The liver enzyme fold changes were calculated using the
upper limit of normal (ULN) for alkaline phosphatase
(ALP) and gamma-glutamyltransferase (GGT), as de-
tailed in Table 3. Eleven out of twelve patients (92%) had
reduction with seven out of twelve patients (58%) show-
ing normalization of ALP levels within 6 months of anti-
TB therapy.
The duration of anti-TB therapy was clearly docu-
mented in seventeen out of twenty patients (85%).
Median duration of anti-TB therapy was 9 months with
a range of 1 to 13 months. Twelve out of twenty patients
(60%) were successfully treated with anti-TB therapy.
Two out of twenty patients (10%) developed drug
resistant TB, one at 6 months and the other at 11
months after liver biopsy. At the time of hepatic TB
diagnosis both had drug susceptible TB based on isolates
from extra-hepatic sites. Both patients died at least one
year after liver biopsy and within 36 months of the diag-
nosis of drug resistant TB. The mortality in our study at
one year post-biopsy was 30% and median time to death
was 4 months (range <1 to 8 months).
Discussion
We characterized the clinical and histopathologic fea-
tures, as well as the response to treatment of hepatic TB
in HIV co-infected patients. In our case series, hepatic
TB occurred mostly in persons with severe immunosup-
pression [14, 15, 22]. The age distribution in this series
closely matched that of HIV infection, due to the close as-
sociation between extra-pulmonary TB and HIV [8, 22].
The clinical features of hepatic TB in our study were
similar to those reported from HIV-uninfected case series
[4, 7, 9]. A notable exception was that two thirds of our
patients had generalized lymphadenopathy, which could
be a manifestation of TB disease or reactive adenopathy
characteristic of HIV infection [23].
Consistent with the findings of others, hepatic TB
caused a disproportionate elevation of the biliary cana-
licular enzymes, likely reflecting an infiltrative pattern by
granulomatous inflammation [7–9, 14, 15, 24, 25]. The
low serum albumin should not be interpreted as a
marker of hepatocellular synthetic dysfunction since it is
influenced by multiple factors such as malnutrition,
chronic infection, chronic inflammation and HIV-
associated nephropathy [7, 8, 14, 26]. Coagulation
studies are a more reliable marker of hepatic function,
however these were normal in our case series which may
imply that granulomatous inflammation does not inter-
fere with hepatocellular function [24].
Eighty five percent (85%) of our case series had fea-
tures of pulmonary tuberculosis suggesting that hepatic
involvement was probably secondary to dissemination
from the lung. However only two chest radiographs
showed the typical pattern of TB lung involvement, a
finding consistent with the severity of the underlying
immunodeficiency [1, 27]. Microbiology of liver tissue
demonstrated poor sensitivity in confirming a diagnosis
of hepatic TB [15, 22]. Prior exposure to anti-TB therapy
might have played a role, and the unreliability of microbiol-
ogy was well recognized in the pre-HIV era [4, 7, 9, 11].
The histologic findings of hepatic TB include epithelioid
granuloma, often with caseation and non-specific reactive
hepatitis [28]. In advanced HIV disease, granuloma forma-
tion in response to mycobacterial infection is poor and may
be associated with increased bacillary presence [15, 25, 29].
Hepatic TB granuloma formation has been well described
in severe HIV disease upon commencement of ART, as a
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manifestation of IRIS [22]. In this study, the histo-
logic findings showed varying degrees of granuloma-
tous inflammation with no relationship between the
CD4 cell count and the presence or absence of granu-
lomatous inflammation. Most of the patients in this
study were not receiving ART, suggesting that a
granulomatous response was possible despite a poorly
functioning immune system. Although a hepatic
granulomatous response may be associated with IRIS
we were not able to draw any conclusions from our
predominantly ART-naïve case series [22].
Due to concerns of exposing patients with unexplained
liver enzyme abnormalities to potentially hepatotoxic
drugs, 15 of the 20 (75%) patients were not commenced
on ART despite clear indication and a further 2 (10%)
on ART had their ART discontinued. Such treatment
delays or interruptions could result in serious conse-
quences. Thus it is important to recognize that the
Table 2 Microbiology and histology results for 20 patients with hepatic tuberculosisa
Pt Microscopyb and culture of sputum and/
or other extrapulmonary site as indicated
within ()
Microbiology of liver tissue Histology of liver tissuea
Culture Sensitivity
1 Smear Negative, Culture Positive for MTB MTB Pansensitive AFB seen with granulomatous inflammation.
2 Smear Negative, Culture Positive for MTB MTB Pansensitive AFB seen. Granulomatous inflammation
consistent with TB.
3 Smear Positive for MTB MTB Pansensitive AFB seen. Granulomatous inflammation
consistent with TB.
4 Smear Positive for MTB No growth N/A AFB seen. Granulomatous inflammation
consistent with TB.
5 Smear Positive for MTB MTB Pansensitive AFB seen. Granulomatous inflammation
consistent with TB.
6 Smear Negative, Culture Positive for MTB Not done N/A AFB seen with granulomatous inflammation
and features of Schistosomiasis.
7 Smear Positive for MTB MTB Pansensitive AFB seen. Granulomatous inflammation
consistent with TB.
8 Smear Positive for MTB No growth N/A AFB seen. Granulomatous inflammation
consistent with TB.
9 N/A; (bone marrowc) Not done N/A AFB seen. Granulomatous inflammation
consistent with TB. Hepatitis B positived
10 Smear Positive for MTB Not done N/A AFB seen. Granulomatous inflammation
consistent with TB.
11 Smear Positive for MTB Not done N/A AFB seen. Granulomatous inflammation
consistent with TB.
12 N/A; (AFB positive on blood culture smear) AFB growne Not done AFB seen with granulomatous inflammation.
13 N/A; (cervical lymph nodec; ascitic fluidc) No growth N/A Granulomatous inflammation consistent
with TB.
14 Smear Positive for MTB No growth N/A Granulomatous inflammation consistent
with TB.
15 Negative; (pleural effusionc) No growth N/A Granulomatous inflammation.
16 N/A No growth N/A Granulomatous inflammation consistent
with TB.
17 Smear Positive for MTB Not done N/A AFB seen with granulomatous inflammation.
18 Negative No growth N/A AFB seen. Granulomatous inflammation
consistent with TB.
19 Smear Negative, Culture Positive for MTB No growth N/A Features suspicious of Hodgkin’s.
Granulomatous inflammation, ZN negative.f
20 Smear Positive for MTB Not done N/A Granulomatous inflammation.
aLiver histology specimens were stained with Ziehl Neelsen stain to detect acid-fast bacilli. Granulomatous inflammation consistent with TB infers caseating granulomas
with foci of activated macrophages (epithelioid cells), rimmed by fibroblasts, lymphocytes, histiocytes and occasional multinucleated giant cells [20]. Pt Patient;
bAuramine O stain, MTB Mycobacterium Tuberculosis; AFB acid-fast bacilli, TB Tuberculosis, N/A Not applicable; cCulture from this biopsy site was positive for MTB;
dImmunohistochemistry positive for Hepatitis B virus surface and core antigen; especies not identified; ZN Ziehl Neelsen; fhistology of bone marrow aspirate showed
AFB and granulomatous inflammation consistent with TB
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described liver enzyme abnormalities, in the context of
TB at other sites, is possibly indicative of hepatic TB
and should not unnecessarily delay ART.
Optimal duration of anti-TB therapy for hepatic
involvement remains unclear [15] and changes in liver
enzyme abnormalities may be used to monitor response
to anti-TB therapy. Based on trends of liver enzyme
changes available for twelve patients, liver enzyme levels
should normalize in most patients within six months of
anti-TB therapy. However, it is unclear if one should use
normalization of the liver enzyme abnormalities to de-
termine when to discontinue treatment. Literature shows
that there may be up to 30% variability of liver enzymes
due to patient factors [30] and in some of our patients,
enzyme abnormalities resolved several months after ces-
sation of anti-TB therapy.
The treatment success rate in our case series was
lower than that reported for sub-Saharan Africa [2]. Ad-
vanced immunosuppression may have contributed to the
high mortality rate, consistent with other TB studies [3].
Our study does have some limitations. Patients de-
scribed in our study were all managed in an Infectious
Diseases Unit at King Edward VIII hospital, which is a
tertiary level institute. Hence, it is likely that many pa-
tients with possible hepatic TB were managed empiric-
ally, based on evidence of TB in other organ systems, at
the peripheral health care facility. Therefore, this case
series represents a more select group with a particularly
high suspicion of hepatic TB. Furthermore, patterns of
liver enzyme abnormalities might have biased patient
selection for liver biopsy.
Like any retrospective case series study design, we
cannot draw any conclusions regarding incidence or
prevalence of disease [31]. However, our observations
highlight when one should be suspicious of hepatic TB
and offers guidance on monitoring response of hepatic
TB to anti-TB therapy.
Conclusion
Clinicians should maintain a high index of suspicion for
hepatic TB, especially among HIV-infected patients with
elevated liver enzymes and evidence of TB in other
organ systems. The presence of unexplained hepatomeg-
aly and preserved liver synthetic function are additional
supportive features. Such enzyme abnormalities should
not delay the initiation of ART. Granulomatous reac-
tions are a common histopathologic finding even in ad-
vanced HIV disease and microbiology of liver tissue has
a role in the diagnosis of hepatic TB. Evolution of liver
enzyme abnormalities in response to anti-TB therapy
might serve as a useful monitoring tool but the decision
to discontinue anti-TB therapy should not depend on
normalization of liver enzymes since this may take sev-
eral months to occur.
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Table 3 Fold change in Alkaline Phosphatase (ALP) and
Gamma-Glutamyltransferase (GGT)
Alkaline Phosphatase Gamma-Glutamyltransferase
Patient Baseline 1 month 6 month Baseline 1 month 6 month
1 25 11 1.5 25 16 6
2 <ULN <ULN <ULN 2 1 <ULN
4 4.5 5 <ULN 7.5 13 <ULN
6 3.5 6.5 <ULN 5.5 17 2
8 2.5 2.5 4 6.5 4 1
9 2 1 <ULN <ULN <ULN <ULN
10 1.5 2.5 <ULN 6.5 9.5 6.5
13 2 4.5 1.5 2.5 5.5 1
14 17.5 7 5.5 20 9.5 16.5
15 3.5 5.5 <ULN 9 10 2.5
16 <ULN 3 <ULN <ULN 3 <ULN
17 9.5 8.5 3.5 19.5 13 5.5
Fold change is calculated by dividing patients’ value by upper limit of normal
(ULN). Alkaline phosphatase ULN = 121 U/L, Gamma Glutamyltransferase
ULN = 60 U/L
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